Avingtrans (AVG) investor relations material

Medical & industrial imaging division strategy and vision

• Targeting a $150m revenue by 2031 through diversified X-ray and magnetics platforms, with strong positions in orthopaedic imaging, quantum computing, and industrial inspection.

• Focus on layered technology platforms leveraging shared magnet and imaging IP for multiple revenue streams.

• Four global locations generated £5m revenue in FY2025, with expansion in the US, UK, and Australia.

Orthopaedic imaging and Adaptix Ortho350

• Adaptix Ortho350 offers portable, low-dose 3D X-ray imaging, addressing limitations of traditional 2D X-ray and providing a cost-effective alternative to CT.

• FDA cleared in November 2025, with first US resellers signed in Q1 2026 and a US revenue vision of $30m by 2031.

• Demonstrated clinical impact with faster, more confident diagnoses and improved patient experience.

• Capacity release model projects >$900,000 annual additional revenue per institution by freeing up CT/MRI slots.

• Commercial milestones include KOL site installations, CPT coding validation, and expansion of reseller network through FY2027.

MRI imaging and Magnetica Compact MRI

• Compact, helium-free 3T MRI system targets high-quality imaging at lower cost and smaller footprint, expanding access to decentralized MSK sites.

• First system due for FDA submission in December 2026, with a revenue vision of $60m by 2031.

• Compact system offers same imaging quality as full body 3T MRI at 25% of the weight and 30% of the lifetime cost.